"Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial." New England Journal of Medicine 2023;389:514526 Wilding JPH, et al
doi: 10.3389/fonc.2024.1448112 Received 12 June 2024 Accepted 14 August 2024 Published 29 August 2024 Volume 14 - 2024 Edited by Jiang Chen, Zhejiang University, China Reviewed by Zhenhua Li, Harvard Medical School, United States Yi Mu, ClinChoice Inc, United States Kunsheng Li, Nanjing Drum Tower Hospital, China Updates Copyright 2024 Chen, Cheng and Zhang
Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical trial
Addressing these priorities will be critical for advancing HDT from preclinical promise to clinical reality, and (4) developing more robust and physiologically relevant in vitro assays and in vivo models that better recapitulate the complex hostpathogen interactions and immune responses observed in human TB
.png)
